Chemotherapy for colorectal cancer liver metastases

Steven Robert Alberts, Lawrence D. Wagman

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a highly prevalent malignant disease in industrialized nations. The annual incidence of invasive CRC in the U.S. is among the highest in the world, and the liver is the only metastatic site in approximately one third of patients. Without treatment, patients with metastatic disease have a poor prognosis; however, long-term survival benefits and even cure have been reported in patients undergoing surgical resection of metastases. In addition, advances in chemotherapy, imaging, and surgical techniques have increased the proportion of patients who are eligible for resection. Combination therapy with fluorouracil and leucovorin has been the mainstay of treatment for metastatic CRC; however, the introduction of newer agents, such as oxaliplatin and irinotecan, and targeted agents, such as cetuximab and bevacizumab, has yielded improvements in response rates (RRs) and survival. Maximizing the exposure of hepatic metastases to high target concentrations of cytotoxic drugs using hepatic arterial infusion (HAI) increases RRs further than with systemic chemotherapy; however, the impact of HAI on survival is unclear. As the goals of chemotherapeutic treatment for metastatic CRC increasingly shift from palliation to prolongation of survival, improvement in RRs, and downsizing of tumors in order to enable or optimize resection, treatment in a multidisciplinary environment involving a medical oncologist, radiologist, and surgical oncologist with hepatobiliary expertise will become central to deciding the best course of therapy and timing of surgery.

Original languageEnglish (US)
Pages (from-to)1063-1073
Number of pages11
JournalOncologist
Volume13
Issue number10
DOIs
StatePublished - 2008

Fingerprint

Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Drug Therapy
oxaliplatin
irinotecan
Liver
Survival
Therapeutics
Leucovorin
Developed Countries
Fluorouracil
Survival Rate
Incidence
Pharmaceutical Preparations
Neoplasms

Keywords

  • 5-fluorouracil
  • Chemotherapy
  • Colorectal cancer
  • Liver metastases
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy for colorectal cancer liver metastases. / Alberts, Steven Robert; Wagman, Lawrence D.

In: Oncologist, Vol. 13, No. 10, 2008, p. 1063-1073.

Research output: Contribution to journalArticle

Alberts, Steven Robert ; Wagman, Lawrence D. / Chemotherapy for colorectal cancer liver metastases. In: Oncologist. 2008 ; Vol. 13, No. 10. pp. 1063-1073.
@article{fef99b81e7494961aeb034cdc7c2e724,
title = "Chemotherapy for colorectal cancer liver metastases",
abstract = "Colorectal cancer (CRC) is a highly prevalent malignant disease in industrialized nations. The annual incidence of invasive CRC in the U.S. is among the highest in the world, and the liver is the only metastatic site in approximately one third of patients. Without treatment, patients with metastatic disease have a poor prognosis; however, long-term survival benefits and even cure have been reported in patients undergoing surgical resection of metastases. In addition, advances in chemotherapy, imaging, and surgical techniques have increased the proportion of patients who are eligible for resection. Combination therapy with fluorouracil and leucovorin has been the mainstay of treatment for metastatic CRC; however, the introduction of newer agents, such as oxaliplatin and irinotecan, and targeted agents, such as cetuximab and bevacizumab, has yielded improvements in response rates (RRs) and survival. Maximizing the exposure of hepatic metastases to high target concentrations of cytotoxic drugs using hepatic arterial infusion (HAI) increases RRs further than with systemic chemotherapy; however, the impact of HAI on survival is unclear. As the goals of chemotherapeutic treatment for metastatic CRC increasingly shift from palliation to prolongation of survival, improvement in RRs, and downsizing of tumors in order to enable or optimize resection, treatment in a multidisciplinary environment involving a medical oncologist, radiologist, and surgical oncologist with hepatobiliary expertise will become central to deciding the best course of therapy and timing of surgery.",
keywords = "5-fluorouracil, Chemotherapy, Colorectal cancer, Liver metastases, Oxaliplatin",
author = "Alberts, {Steven Robert} and Wagman, {Lawrence D.}",
year = "2008",
doi = "10.1634/theoncologist.2008-0142",
language = "English (US)",
volume = "13",
pages = "1063--1073",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Chemotherapy for colorectal cancer liver metastases

AU - Alberts, Steven Robert

AU - Wagman, Lawrence D.

PY - 2008

Y1 - 2008

N2 - Colorectal cancer (CRC) is a highly prevalent malignant disease in industrialized nations. The annual incidence of invasive CRC in the U.S. is among the highest in the world, and the liver is the only metastatic site in approximately one third of patients. Without treatment, patients with metastatic disease have a poor prognosis; however, long-term survival benefits and even cure have been reported in patients undergoing surgical resection of metastases. In addition, advances in chemotherapy, imaging, and surgical techniques have increased the proportion of patients who are eligible for resection. Combination therapy with fluorouracil and leucovorin has been the mainstay of treatment for metastatic CRC; however, the introduction of newer agents, such as oxaliplatin and irinotecan, and targeted agents, such as cetuximab and bevacizumab, has yielded improvements in response rates (RRs) and survival. Maximizing the exposure of hepatic metastases to high target concentrations of cytotoxic drugs using hepatic arterial infusion (HAI) increases RRs further than with systemic chemotherapy; however, the impact of HAI on survival is unclear. As the goals of chemotherapeutic treatment for metastatic CRC increasingly shift from palliation to prolongation of survival, improvement in RRs, and downsizing of tumors in order to enable or optimize resection, treatment in a multidisciplinary environment involving a medical oncologist, radiologist, and surgical oncologist with hepatobiliary expertise will become central to deciding the best course of therapy and timing of surgery.

AB - Colorectal cancer (CRC) is a highly prevalent malignant disease in industrialized nations. The annual incidence of invasive CRC in the U.S. is among the highest in the world, and the liver is the only metastatic site in approximately one third of patients. Without treatment, patients with metastatic disease have a poor prognosis; however, long-term survival benefits and even cure have been reported in patients undergoing surgical resection of metastases. In addition, advances in chemotherapy, imaging, and surgical techniques have increased the proportion of patients who are eligible for resection. Combination therapy with fluorouracil and leucovorin has been the mainstay of treatment for metastatic CRC; however, the introduction of newer agents, such as oxaliplatin and irinotecan, and targeted agents, such as cetuximab and bevacizumab, has yielded improvements in response rates (RRs) and survival. Maximizing the exposure of hepatic metastases to high target concentrations of cytotoxic drugs using hepatic arterial infusion (HAI) increases RRs further than with systemic chemotherapy; however, the impact of HAI on survival is unclear. As the goals of chemotherapeutic treatment for metastatic CRC increasingly shift from palliation to prolongation of survival, improvement in RRs, and downsizing of tumors in order to enable or optimize resection, treatment in a multidisciplinary environment involving a medical oncologist, radiologist, and surgical oncologist with hepatobiliary expertise will become central to deciding the best course of therapy and timing of surgery.

KW - 5-fluorouracil

KW - Chemotherapy

KW - Colorectal cancer

KW - Liver metastases

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=55049134360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049134360&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2008-0142

DO - 10.1634/theoncologist.2008-0142

M3 - Article

C2 - 18838438

AN - SCOPUS:55049134360

VL - 13

SP - 1063

EP - 1073

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -